SLC5A2 and heart disorder: The antifibrotic effect of SGLT2 inhibitors might be particularly relevant to cardiac diseases in both humans and veterinary species characterized by substantial fibrosis, including many of the arrhythmogenic cardiomyopathies (Yang et al., 2022).